The catch: authorized and regulatory certainty is minimal. Retatrutide was never ever to the FDA drug scarcity listing (since it was never ever accredited), so compounders presenting it run beneath far more tenuous legal framing than those that handled semaglutide or tirzepatide during the 2023–2024 shortages. Pricing may change as enforcement ev